Oral Drug Combination Extends PFS in Advanced Breast Cancer

Here’s a summary of the key data from the provided text:

* ⁤ Giredestrant & Everolimus Show Promise: A new combination therapy of giredestrant and everolimus is showing positive ⁣results in treating metastatic ER-positive,​ HER-2-negative breast cancer.
* Improved Disease Control: The evERA study demonstrated substantially improved disease control with this combination compared to standard treatment.
* Addressing Resistance: This combination is designed to overcome common resistance mechanisms to ‍existing breast cancer therapies.
* Manageable Safety: ‌The safety profile of the giredestrant regimen was considered manageable.
* Immature Survival Data: While overall survival data isn’t yet conclusive, it’s currently trending ⁣positively.
* Source: The information is provided by Dana-Farber Cancer Institute.